First Republic Investment Management Inc. Buys Shares of 5,274 TESARO Inc (TSRO)

First Republic Investment Management Inc. bought a new stake in shares of TESARO Inc (NASDAQ:TSRO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 5,274 shares of the biopharmaceutical company’s stock, valued at approximately $680,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TSRO. Hanseatic Management Services Inc. grew its position in TESARO by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 5,936 shares of the biopharmaceutical company’s stock valued at $830,000 after acquiring an additional 15 shares during the last quarter. Stephens Inc. AR grew its position in TESARO by 6.5% in the 2nd quarter. Stephens Inc. AR now owns 1,874 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 115 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its position in TESARO by 1.1% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 12,092 shares of the biopharmaceutical company’s stock valued at $1,690,000 after acquiring an additional 136 shares during the last quarter. Aperio Group LLC grew its position in TESARO by 4.5% in the 2nd quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock valued at $512,000 after acquiring an additional 156 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its position in TESARO by 15.4% in the 2nd quarter. Advisors Asset Management Inc. now owns 4,076 shares of the biopharmaceutical company’s stock valued at $570,000 after acquiring an additional 543 shares during the last quarter.

Shares of TESARO Inc (NASDAQ:TSRO) opened at $80.58 on Friday. TESARO Inc has a 1-year low of $77.20 and a 1-year high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.

TESARO (NASDAQ:TSRO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The business had revenue of $142.77 million during the quarter, compared to analysts’ expectations of $130.57 million. During the same period in the prior year, the business earned ($1.72) EPS. The business’s revenue for the quarter was up 740.3% compared to the same quarter last year. equities research analysts predict that TESARO Inc will post -8.17 EPS for the current fiscal year.

Several equities analysts have commented on the company. Credit Suisse Group set a $190.00 price objective on TESARO and gave the company a “buy” rating in a research report on Friday, August 18th. HC Wainwright reaffirmed a “buy” rating and issued a $158.00 price objective on shares of TESARO in a research report on Monday, November 20th. SunTrust Banks reaffirmed a “buy” rating and issued a $160.00 price objective on shares of TESARO in a research report on Friday, November 10th. Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $117.00 price objective on shares of TESARO in a research report on Monday, October 23rd. Finally, Zacks Investment Research raised TESARO from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. TESARO presently has a consensus rating of “Buy” and an average price target of $159.39.

In related news, Director James O. Armitage sold 10,000 shares of the company’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the completion of the sale, the director now directly owns 10,000 shares in the company, valued at approximately $1,171,300. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of the company’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $118.60, for a total value of $70,211.20. Following the sale, the senior vice president now owns 6,943 shares of the company’s stock, valued at $823,439.80. The disclosure for this sale can be found here. Insiders sold a total of 11,421 shares of company stock valued at $1,312,175 over the last quarter. Company insiders own 40.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “First Republic Investment Management Inc. Buys Shares of 5,274 TESARO Inc (TSRO)” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2017/12/16/first-republic-investment-management-inc-buys-shares-of-5274-tesaro-inc-tsro.html.

TESARO Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply